What topics does this cannabis study cover?

This study covers research on: Addiction, Endocannabinoid.

Cannabis changes how smokers feel nicotine's unpleasant effects

Q: Where was this research published?

Published in The international journal of neuropsychopharmacology on May 26, 2026.

Recent Cannabis Exposure and Acute Nicotine Effects: Insights from Randomized, Double-Blind, Placebo-Controlled Intravenous Nicotine Studies.

The international journal of neuropsychopharmacology • May 26, 2026 • Moderately Relevant

🤖

AI Summary

This groundbreaking study examined how recent cannabis use affects the way smokers respond to nicotine. Researchers conducted randomized, double-blind, placebo-controlled experiments using intravenous nicotine on 60 tobacco smokers, comparing those with recent cannabis exposure to those without. The key finding revealed that participants with past-30-day cannabis use reported significantly greater aversive (unpleasant) effects at higher nicotine doses, suggesting that cannabis exposure changes how the body responds to nicotine's negative sensations.

The results show a fascinating neurochemical interaction: nicotine's stimulatory and pleasurable effects increased dose-dependently in all participants, but only those with recent cannabis exposure experienced heightened unpleasant sensations at the 0.2 mg nicotine dose (Cohen's d=0.83, a large effect size). Importantly, this difference in aversive responses did not translate into different nicotine-seeking behavior or abnormal cardiovascular reactions. This suggests that cannabis and nicotine may interact primarily at the brain level, affecting how unpleasant nicotine feels without changing fundamental addiction vulnerability.

These findings have important implications for the millions of people who use both cannabis and tobacco. The study indicates that recent cannabis use might actually amplify the negative sensations of higher nicotine doses, which could theoretically support smoking cessation efforts. However, researchers emphasize this requires further investigation before drawing clinical conclusions. The work opens new research directions into how cannabis exposure reshapes nicotine's effects and may ultimately inform better cessation strategies for this common dual-use population.

📄 Original Abstract

Cannabis-nicotine co-use is common and may affect cessation outcomes, yet whether recent cannabis exposure alters nicotine's acute effects in humans remains unclear. We examined whether recent, non-daily cannabis exposure modulates the acute subjective effects of intravenous nicotine. We pooled data from two randomized, double-blind, placebo-controlled studies using intravenous (IV) nicotine to isolate nicotine's pharmacodynamics in adults who smoke tobacco cigarettes (N=60). Participants completed three sessions (placebo, 0.1 mg, 0.2 mg nicotine/70 kg). Recent cannabis exposure was defined a priori (past-30-day use with positive urine THC-COOH vs no past-30-day use with negative screen). Primary outcomes were peak Drug Effects Questionnaire (DEQ) composites-stimulatory, pleasurable, aversive-within 10 minutes post-infusion. Secondary outcomes included nicotine self-administration behavior (proportion of nicotine choices) and cardiovascular responses (heart rate, blood pressure). Linear mixed-effects models included dose, cannabis exposure, sex, and FTND. Results: Nicotine increased all DEQ domains dose-dependently (p<.0001). Aversive effects showed a significant dose x cannabis exposure interaction (χ2=13.31, p=.001): participants with recent cannabis exposure reported greater aversive responses at 0.2 mg (Cohen's d'=0.83), with minimal between-group differences at placebo/0.1 mg. Nicotine self-administration did not differ by cannabis exposure status, and no dose x cannabis exposure interactions were observed for cardiovascular responses. Recent, non-daily cannabis exposure is thus associated with selectively greater aversive responses to a clinically relevant IV nicotine dose, without differential cardiovascular reactivity or altered nicotine choice. These findings support a shift in the aversive limb of nicotine's dose-response and inform mechanistic and clinical studies on how cannabis exposure shapes nicotine reinforcement and cessation outcomes.Clinical trial registration: NCT01495819, https://clinicaltrials.gov/study/NCT01495819.